EC Number | Application | Comment | Organism |
---|---|---|---|
3.3.2.6 | medicine | understanding the molecular alterations that influence primary effusion lymphoma development will aid in the identification of novel therapeutic targets, as well as potential risk factors for this desease | Homo sapiens |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.3.2.6 | (7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O | Homo sapiens | - |
(6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.3.2.6 | Homo sapiens | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.3.2.6 | BCBL-1 cell | primary effusion lymphoma | Homo sapiens | - |
3.3.2.6 | BJAB cell | - |
Homo sapiens | - |
3.3.2.6 | L-428 cell | classical Hodgkins disease | Homo sapiens | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.3.2.6 | (7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O | - |
Homo sapiens | (6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.3.2.6 | leukotriene-A4 hydrolase | - |
Homo sapiens |
3.3.2.6 | LTA4H | - |
Homo sapiens |